Scholarlink

<p>The novel ligand (H<sub>2</sub>L), N’-(2-cyanoacetyl)isonicotinohydrazide, has been synthesized <i>via</i> reacting the isonicotinic hydrazide with 1-cyanoacetyl-3,5-dimethylpyrazole. The keto-form of the free ligand has been evoked from its spectral data. Based on elemental analyses and mass spectra, the ligand formed 1:1 (M: L) metal complexes with the acetate salts of Cu(II), Co(II), Ni(II) and Zn(II). The complexes’ spectral analyses revealed that the ligand behaved as a mononegative bidentate <i>via</i> the hydrazonyl N<sup>1</sup> and deprotonated enolized acetyl oxygen. Moreover, the DFT quantum chemical calculations revealed that the ligand had higher HOMO and lower LUMO energies than metal complexes, implying an electron donating character. Furthermore, the in vitro anticancer activity against HepG2 and HCT-116 cell lines displayed that the ligand was more potent than doxorubicin against both cell lines, although the metal complexes displayed lower efficacy.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Synthesis, characterization and cytotoxic evaluation of metal complexes derived from new N′-(2-cyanoacetyl)isonicotinohydrazide

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月27日

查看全文
  • Mohamed H. Abdel-Rhman,
  • Ghada Samir,
  • Nasser M. Hosny

摘要

The novel ligand (H2L), N’-(2-cyanoacetyl)isonicotinohydrazide, has been synthesized via reacting the isonicotinic hydrazide with 1-cyanoacetyl-3,5-dimethylpyrazole. The keto-form of the free ligand has been evoked from its spectral data. Based on elemental analyses and mass spectra, the ligand formed 1:1 (M: L) metal complexes with the acetate salts of Cu(II), Co(II), Ni(II) and Zn(II). The complexes’ spectral analyses revealed that the ligand behaved as a mononegative bidentate via the hydrazonyl N1 and deprotonated enolized acetyl oxygen. Moreover, the DFT quantum chemical calculations revealed that the ligand had higher HOMO and lower LUMO energies than metal complexes, implying an electron donating character. Furthermore, the in vitro anticancer activity against HepG2 and HCT-116 cell lines displayed that the ligand was more potent than doxorubicin against both cell lines, although the metal complexes displayed lower efficacy.